The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL - Flinn, Ian W.; Hillmen, Peter; Montillo, Marco; Nagy, Zsolt; Illés, Árpád; Etienne, Gabriel; Delgado, Julio; Kuss, Bryone J.; Tam, Constantine S.; Gasztonyi, Zoltán; Offner, Fritz; Lunin, Scott; et al. (Blood, 2018)
Keywords: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials and Observations; Disease-Free Survival; Double-Blind Method; Female; Humans; Isoquinolines - administration & dosage; Isoquinolines - adverse effects; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Life Sciences; Male; Middle Aged; Purines - administration & dosage; Purines - adverse effects; Recurrence; Smith-Magenis Syndrome; Survival Rate; Tumor Suppressor Protein p53 - genetics